PMID- 18473993
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20191110
IS  - 1574-8871 (Print)
IS  - 1574-8871 (Linking)
VI  - 2
IP  - 2
DP  - 2007 May
TI  - Receptor tyrosine kinases as therapeutic targets in malignant glioma.
PG  - 87-101
AB  - Malignant gliomas have retained their dismal prognosis despite aggressive 
      multimodal conventional therapeutic approaches, illustrating the need for novel 
      therapeutic strategies. Recent advances in the cellular and molecular biology of 
      gliomas have enhanced our understanding of the role of receptor tyrosine kinases 
      (RTK) and RTK-mediated signal transduction pathways in tumor initiation, 
      maintenance, angiogenesis, and vascular proliferation. Special attention has been 
      focused on targets such as epidermal growth factor receptors (EGFR), 
      platelet-derived growth factor receptors (PDGFR), vascular endothelial growth 
      factor receptors (VEGFR), and on pathways such as the Ras/Raf/mitogen-activated 
      protein (MAP)-kinase and phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian 
      target of rapamycin (mTOR) pathways. Novel targeted drugs known as small molecule 
      inhibitors have been shown to modify the activity of these receptors and 
      signaling pathways. Thus far, however, small molecule RTK inhibitor development 
      has concentrated on a few RTK only, and drug activity has been comprehensively 
      evaluated only in a limited number of different malignancies. One of the limiting 
      factors for novel drug design and development is the incomplete knowledge of RTK 
      functions in malignant glioma. This review summarizes current basic and clinical 
      knowledge on the role of RTK in malignant glioma and on their importance as 
      targets for new forms of therapy.
FAU - Ren, H
AU  - Ren H
AD  - Department of Immunology, Harbin Medical University, Harbin, PR China. 
      huan_ren@hotmail.com
FAU - Yang, B F
AU  - Yang BF
FAU - Rainov, Nikolai G
AU  - Rainov NG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Rev Recent Clin Trials
JT  - Reviews on recent clinical trials
JID - 101270873
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Enzyme Inhibitors/*pharmacology
MH  - Glioma/*drug therapy
MH  - Humans
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
MH  - Signal Transduction/*drug effects
RF  - 216
EDAT- 2008/05/14 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/05/14 09:00
PHST- 2008/05/14 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/05/14 09:00 [entrez]
AID - 10.2174/157488707780599384 [doi]
PST - ppublish
SO  - Rev Recent Clin Trials. 2007 May;2(2):87-101. doi: 10.2174/157488707780599384.